We’re seeking transformative ideas in drug discovery

Successful DPAc collaborations have one thing in common: they’re built from an innovative idea with the potential to address an unmet medical need. We choose an idea for its innovative science and for the benefits that may emerge from it, especially its potential impact on clinical outcomes. Projects can come from almost any disease area or treatment modality.

More specifically, we are interested in collaborating on:

  • Small molecule and biological (protein) modalities
  • Early stage discovery projects; it is not necessary to have molecular assets or patents
  • Therapeutic hypotheses linking target/pathway to disease, built on genetic evidence, human expression data, in vitro cellular data and in vivo mechanistic models

What are we looking for?

Clear therapeutic hypothesis

A coherent, supportable hypothesis exists to explain how a target will produce a physiological effect or effects with significant benefit to particular patients

Unique drug target or pathway

A specific drug target has been identified, with some understanding of type of pharmacology desired

Tractability

Target knowledge suggests that a drug-like molecule can be generated; disease knowledge suggests that opportunity can be evaluated effectively in the clinic

Exclusive enabling expertise

The academic has relevant expertise essential to progressing the target that is not (readily) found elsewhere

Your requirement for GSK contribution

GSK has capabilities and expertise that will help progress the project to the next milestone

If you have a therapeutic idea that meets the DPAc criteria, the next step is to submit a one-page, non-confidential application in your region.